Litcius/Paper detail

Exploring the potential of ruthenium(<scp>ii</scp>)–phosphine–mercapto complexes as new anticancer agents

Marcos V. Palmeira‐Mello, Analu R. Costa, Leticia P. de Oliveira, Olivier Blacque, Gilles Gasser, Alzir A. Batista

2024Dalton Transactions14 citationsDOIOpen Access PDF

Abstract

H} NMR spectroscopies. Since enzymes from the P-450 system play a crucial role in cellular detoxification and metabolism, the microsomal stability of 1, which was found to be the most interesting compound of this study, was investigated using human microsomes to verify its potential oxidation in the liver. The analyses by LC-MS and ESI-MS reveal three main metabolites, obtained by oxidation in the dppen and bipy moieties. Moreover, 1 was able to interact with human serum albumin (HSA). The cytotoxicity of the metal complexes was tested in different cancerous and non-cancerous cell lines. Complex 1 was found to be more selective than cisplatin against MDA-MB-231 breast cancer cells when compared to MCF-10A non-cancerous cells. In addition, complex 1 affects cell morphology and migration, and inhibits colony formation in MDA-MB-231 cells, making it a promising cytotoxic agent against breast cancer.

Topics & Concepts

PhosphineRutheniumAnticancer drugCombinatorial chemistryChemistryMetalStereochemistryMedicinal chemistryDrugOrganic chemistryPharmacologyBiologyCatalysisMetal complexes synthesis and propertiesFerrocene Chemistry and ApplicationsOrganometallic Complex Synthesis and Catalysis